News | August 07, 2021
Bafna Pharma posts Q1FY 21-22 net at Rs. 2.08 Cr
This robust growth has come despite the raging pandemic for most part of the quarter
This robust growth has come despite the raging pandemic for most part of the quarter
CDSCO to fast-track trials and approval for COVID19 vaccine
He will be stationed at the company HQ in Bengaluru, India
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
MitraClip implants give a new lease of life for frail and elderly patients who cannot go in for conventional open-heart surgery
The company has been consistently reducing debt
The data should be submitted by August 12th 2021
Deal for 100 million doses with additional 100 million through 2023
Innovative solutions and a deep understanding of the market makes this a unique combination
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
